ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
133.157,69
0,11%
S&P 500
5.742,50
-0,05%
US Dollar vs BRL
5,4302
-0,15%
Bitcoin
66.201,88
1,56%
Brent Oil
71,66
1,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Reino Unido
  5. AQSE
  6. HUTCHMED China Limited (HCM.GB)

  7. HUTCHMED China Limited (HCM.GB) Notícias

HCM.GB

HUTCHMED China (HCM.GB)

HUTCHMED China Limited
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:AQSE:HCM.GB
DataHoraFonteTítuloCódigoCompanhia
29/12/202305:30UK RegulatoryHutchmed (China) Limited Total Voting RightsAQSE:HCM.GBHUTCHMED China Limited
29/12/202305:30UK RegulatoryHutchmed (China) Limited Blocklisting Six Monthly ReturnAQSE:HCM.GBHUTCHMED China Limited
21/12/202307:00UK RegulatoryHutchmed (China) Limited Overseas Regulatory AnnouncementAQSE:HCM.GBHUTCHMED China Limited
09/11/202304:00UK RegulatoryHutchmed (China) Limited U.S. FDA Approval of FRUZAQLA(TM) (fruquintinib)AQSE:HCM.GBHUTCHMED China Limited
24/10/202305:30UK RegulatoryHutchmed (China) Limited Vesting of awards under the LTIPAQSE:HCM.GBHUTCHMED China Limited
14/09/202305:30UK RegulatoryHutchmed (China) Limited Director's Share DealingAQSE:HCM.GBHUTCHMED China Limited
21/08/202303:00UK RegulatoryHutchmed (China) Limited Sovleplenib Phase 3 Study Meets Primary EndpointAQSE:HCM.GBHUTCHMED China Limited
07/08/202305:30UK RegulatoryHutchmed (China) Limited Exercise of Share Options by a DirectorAQSE:HCM.GBHUTCHMED China Limited
31/07/202308:00UK RegulatoryHutchmed (China) Limited Interim Results and Business UpdatesAQSE:HCM.GBHUTCHMED China Limited
13/07/202305:30UK RegulatoryHutchmed (China) Limited Changes to Board and Technical CommitteeAQSE:HCM.GBHUTCHMED China Limited
26/06/202305:30UK RegulatoryHutchmed (China) Limited HUTCHMED to Announce 2023 Half-Year ResultsAQSE:HCM.GBHUTCHMED China Limited
16/06/202303:00UK RegulatoryHutchmed (China) Limited Phase III FRESCO-2 Results in The LancetAQSE:HCM.GBHUTCHMED China Limited
15/06/202311:39UK RegulatoryHutchmed (China) Limited MAA of Fruquintinib Validated by the EMAAQSE:HCM.GBHUTCHMED China Limited
06/06/202306:00UK RegulatoryHutchmed (China) Limited LTIP and Share Option SchemeAQSE:HCM.GBHUTCHMED China Limited
26/05/202303:00UK RegulatoryHutchmed (China) Limited Fruquintinib NDA Granted Priority Review by FDAAQSE:HCM.GBHUTCHMED China Limited
17/05/202305:30UK RegulatoryHutchmed (China) Limited Standard form for notification of major holdingsAQSE:HCM.GBHUTCHMED China Limited
12/05/202309:15UK RegulatoryHutchmed (China) Limited Annual General Meeting Poll ResultsAQSE:HCM.GBHUTCHMED China Limited
12/05/202305:30UK RegulatoryHutchmed (China) Limited Board of Directors and Board Committee MembershipAQSE:HCM.GBHUTCHMED China Limited
10/05/202305:30UK RegulatoryHutchmed (China) Limited Appointment of Independent NEDAQSE:HCM.GBHUTCHMED China Limited
11/04/202305:30UK RegulatoryHutchmed (China) Limited 2022 Annual Report and Notice of AGMAQSE:HCM.GBHUTCHMED China Limited
11/04/202305:30UK RegulatoryHutchmed (China) Limited Intended Retirement of Independent NEDAQSE:HCM.GBHUTCHMED China Limited
28/02/202305:30UK RegulatoryHutchmed (China) Limited 2022 Full Year Results and Business UpdatesAQSE:HCM.GBHUTCHMED China Limited
31/01/202305:30UK RegulatoryHutchmed (China) Limited Notice of ResultsAQSE:HCM.GBHUTCHMED China Limited
23/01/202305:00UK RegulatoryHutchmed (China) Limited License to Takeda for Fruquintinib outside ChinaAQSE:HCM.GBHUTCHMED China Limited
18/01/202311:30UK RegulatoryHutchmed (China) Limited Inclusion of ORPATHYS in NRDL in ChinaAQSE:HCM.GBHUTCHMED China Limited
15/11/202204:00UK RegulatoryHutchmed (China) Limited HUTCHMED Announces Strategy UpdateAQSE:HCM.GBHUTCHMED China Limited
14/11/202204:00UK RegulatoryHutchmed (China) Limited Positive Topline Phase 3 Result in FruquintinibAQSE:HCM.GBHUTCHMED China Limited
14/09/202207:00UK RegulatoryHutchmed (China) Limited Share Option Scheme and Long Term Incentive PlanAQSE:HCM.GBHUTCHMED China Limited
08/09/202203:00UK RegulatoryHutchmed (China) Limited FRESCO-2 Colorectal Cancer MRCT Data HighlightsAQSE:HCM.GBHUTCHMED China Limited
23/08/202206:00UK RegulatoryHutchmed (China) Limited Holding(s) in CompanyAQSE:HCM.GBHUTCHMED China Limited
 Apresentando as notícias mais relevantes sobre:AQSE:HCM.GB

Seu Histórico Recente

BIT
LABL
L&G Global Brands UCITS ...
LSE
MF44
Roy.bk.can.23
COIN
PEXTUSD
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados